This action, unlike current drugs used against breast cancer (e.g., tamoxifen), seemed to be specifically addressed on breast tumor cells (which express GLUT5) with independence of estrogen-receptor status [103]. The gene discussed is SLC2A5; the disease is breast carcinoma.